toxicologists. It achieves a fair degree of safety within the confines of known parameters but, conversely, ignores the possibility of detecting hazards not recognized as such. It is very expensive in terms of money, animals and human resources, and adds nothing to our understanding of basic biological processes or toxicological mechanisms. In addition, there have been claims that the imposition of such regulatory burdens has imposed a serious handicap on the development of the chemical industry, especially in its more specialized forms such as pharmaceuticals or agrochemicals.
Given these adverse consequences, the time is appropriate to reconsider our basic approach and perhaps to consider a system more in tune with the needs of society and industry. Such a system would not seek to ensure an absence of hazard based on its identification at any dosage, but would seek to ensure an absence of hazard at the intended level of use. It would also seek to detect such hazard by an examination of the specific biological processes affected.
If we confine our attention to food chemicals and do not consider handling hazards applicable to manufacturing processes, i.e. consider only the hazards to the consumer, a number of questions present themselves which may be arranged as an algorithm (Fig. I) . ( I ) Is anything known about this chemical or chemicals of this type that allows us to predict toxicity? There is an increasing amount of information which could be worked into programmes for narrowing down areas of ignorance about hazardous chemicals. The whole topic of structure-function analyses is ripe for a concerted attack based on accumulated experience (Cramer et al. 1978) . (2) Is there detectable absorption at intended levels of exposure and, if so, is there distribution or accumulation in tissues known to be vulnerable? Tissues such as bone marrow, central nervous system and germinal epithelium are assumed to be of greater importance as target tissues than, for example, liver and kidney which have substantial reserves and powers of regeneration. If such localization can be detected, or if the half-life of the material is prolonged, subacute studies should be undertaken. Similarly, if a chemical is absorbed, placental localization or transfer should be measured, and if it occurs some form of teratological screen undertaken. If absorption does not occur, there remains the possibility of local gut damage. (3) Subacute studies cannot give an indication of potential carcinogenesis that might be present on long-term administration. There is now a well established, though not effectively evaluated, screening procedure for determining the ability of a chemical to interact with DNA to provoke mutation, utilizing bacteria (McCann et al. 1975) . Such tests do not give any information on the potency of the reaction or its relevance to mammalian systems. They are capable of detecting those circumstances where a compound which covalently binds with DNA, damages that DNA to an extent which could cause mutation if adequate repair did not occur. They should therefore be preceded by some assessment of the ability of the suspect compound to bind covalently with mammalian DNA, that is to form macromolecular adducts. If such binding occurs, then it would be appropriate to determine if adverse consequences could ensue by using the Ames test or similar procedure. that a compound may induce some kind of immunological response, or might be instrumental in inhibiting or distorting immunological mechanisms, and this should be looked for specifically. The scheme as presented here includes no indication of the methodology to be used because this is subject to the results of further research. It is clear that there is not enough information available at this time to establish this approach as a regulatory procedure, but the principle on which it is based-namely that the toxicity of a food chemical is related to the rate of absorption and to the tissue concentrations, and that these depend in part on the amounts in food-could be accepted on the basis of current knowledge.
Further research is needed to establish the procedures based on an understanding of some of the mechanisms involved. It is neither necessary nor possible to base any regulatory procedure on complete elucidation of toxicological mechanisms, but it should be possible to identify key events that are recognized as crucial to the development of the disease process under consideration. Some areas of research which then present themselves include; ( I ) structurefunction analysis: this might be nothing more than a process of accumulating information and systems of analysis, but it seems possible that enough is now known about many toxicological processes to be able to make positive associations between molecular configuration and adverse pharmacological or biochemical consequences. (2) The feasibility of low dosage pharmaco-kinetics and its predictability from high dose studies. This includes the relationship between dosage and tissue distribution and metabolism. There is the related topic of repeated dosage on a subacute basis (say 14-28 d), the possibility of accumulation and related toxicity. Is there a relationship between dose and duration in promoting tissue pathology? (3) The relationship between placental localization or transfer, foetal pharmaco-kinetics and teratology. (4) Is it a feasible proposition that electrophilic compounds that do not covalently bind with macromolecules, cannot cause damage to DNA? Is there a relationship between this and the inhibition of DNA repair? Is it possible that reactivity with DNA is a very simple and common phenomenon, and that it is the consequent control of this which is the important factor in mutagenesis or carcinogenesis? ( 5 ) What is the optimum method for detecting that an immune reaction is in progress? Should we be looking at populations of specialized lymphocytes or is it simply enough to weigh the thymus during a subacute study? Is there evidence that some chemicals can impede the immune process? Is this important?
The regulatory process embodied in this scheme would require several pieces of A positive answer to any of these questions could trigger longer term studies utilizing 'no effect levels' of a more specific type. Negative answers would result in clearance, to be reviewed at regular intervals. Whether present systems could be adapted to this scheme remains to be seen, but it seems possible, especially in the UK where there is a tradition of assessment by scientists rather than the widespread use of 'checklists'.
It seems likely that the proposed approach would result in better qualitative information on which to base an assessment of human hazard. There would be a series of positive or negative findings with no room for judgements in terms of hazardous dosage. This is essentially because the initial testing is done at levels 
